Novo Nordisk, Teva ink generic Victoza settlement
Novo Nordisk announced that a settlement between Novo Nordisk and Teva Pharmaceuticals has been reached on the U.S. patent litigation case for Victoza. Consequently, Teva is licensed to launch a generic version of Victoza as of Dec. 22, 2023.
Under certain circumstances, Teva could launch a generic earlier, but not before Mar. 22, 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza on the market, according to the company.
If Novo Nordisk is granted six months pediatric extension for Victoza, all above-mentioned timelines will be extended by six months. All other terms of the agreement are confidential.
The agreement is subject to review by the Federal Trade Commission and the Department of Justice.
“This settlement reflects the comprehensive U.S. patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges,” Novo Nordisk executive vice president and head of biopharm and legal affairs Jesper Brandgaard said.
Under certain circumstances, Teva could launch a generic earlier, but not before Mar. 22, 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza on the market, according to the company.
If Novo Nordisk is granted six months pediatric extension for Victoza, all above-mentioned timelines will be extended by six months. All other terms of the agreement are confidential.
The agreement is subject to review by the Federal Trade Commission and the Department of Justice.
“This settlement reflects the comprehensive U.S. patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges,” Novo Nordisk executive vice president and head of biopharm and legal affairs Jesper Brandgaard said.